Results 41 to 50 of about 14,622,998 (243)
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background Numerous international studies have reported declines in new cancer diagnoses, delayed diagnoses and disruptions in cancer treatment following the implementation of COVID‐19 pandemic public health measures, raising concerns that these effects may ultimately contribute to increased cancer mortality.
Friederike Erdmann +8 more
wiley +1 more source
DNA methylation in follicular lymphoma [PDF]
, 2010 PhDFollicular Lymphoma (FL) is a common B cell Non-Hodgkin Lymphoma with a median survival of 8-10 years. Patients frequently undergo transformation to a more aggressive lymphoma and this is associated with drastically reduced survival.
Ó Riain, Ciarán Liam
core +4 more sources
Therapeutic Apheresis and Dialysis, EarlyView.ABSTRACT Introduction This final analysis of a multicenter, prospective postmarketing surveillance study evaluated the safety of daprodustat in patients with chronic kidney disease anemia in routine clinical practice in Japan. Methods Patients who initiated daprodustat between September 2020 and July 2022 were registered.
Tadao Akizawa +7 more
wiley +1 more source
Extranodal Natural Killer/T-cell Lymphoma, Nasal Type:Diagnosis and Treatment [PDF]
, 2021 The aggressive lymphoma, extranodal natural killer/T-cell lymphoma-nasal type, is strongly associated with Epstein-Barr virus (EBV) and is most common in Asia and in South and Central America. By contrast, incidence is low in the United States and Europe,
Niezink, Anne G H +6 more
core +2 more sources
CAR-T CELL THERAPY IN LYMPHOMAS: EXPANSİON OF INDICATIONS AND NEW APPROACHES
Hematology, Transfusion and Cell TherapyCAR-T (chimeric antigen receptor T-cell) therapy represents a revolutionary advance in treating hematologic cancers, offering promising outcomes for lymphoma patients, especially those with relapsed or refractory disease.
Ayfer Gedük
doaj +1 more source
Frontiers in Oncology, 2022 PurposeThe significance of Epstein-Barr virus (EBV) infections for the prognosis of patients with peripheral T-cell lymphomas (PTCLs), specifically angioimmunoblastic T-cell lymphoma (AITL) and PTCL not otherwise specified (PTCL-NOS), remains unclear ...
Tong-Yoon Kim +16 more
doaj +1 more source
Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation
FEBS Letters, EarlyView.Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang +2 more
wiley +1 more source
Epigenetic reprogramming of lineage switching in cancer
FEBS Letters, EarlyView.Cancer cells rarely commit to a single identity. Epigenetic mechanisms and tumor microenvironment cues push epithelial cells toward flexible, hybrid states that can shift into mesenchymal, neuroendocrine, or stem‐like fates, driving metastasis, drug resistance, and tumor heterogeneity. Targeting the epigenetic regulators behind these transitions, using
Ezgi Boyvatlı +4 more
wiley +1 more source
Anaplastic large-cell lymphoma.
, 2011 The concept of anaplastic large-cell lymphoma (ALCL) has changed over the years because of a stream of new information and novel understanding regarding the cell of origin, biology, genetics, and clinical features of these neoplasms. This new information
European T. Cell Lymphoma Study Group +3 more
core +1 more source
Peripheral T-cell lymphoma: Frequency and distribution in a tertiary referral center in South India
Indian Journal of Pathology and Microbiology, 2012 Background and Aim: Peripheral T/NK-cell lymphomas are uncommon types of non-Hodgkin′s lymphoma (NHL) with a higher frequency in Far East countries as compared to the West.
Deepak K Burad +2 more
doaj +1 more source